DK1007088T3 - Rekombinant svine-adenovirusvektor - Google Patents

Rekombinant svine-adenovirusvektor

Info

Publication number
DK1007088T3
DK1007088T3 DK98938527T DK98938527T DK1007088T3 DK 1007088 T3 DK1007088 T3 DK 1007088T3 DK 98938527 T DK98938527 T DK 98938527T DK 98938527 T DK98938527 T DK 98938527T DK 1007088 T3 DK1007088 T3 DK 1007088T3
Authority
DK
Denmark
Prior art keywords
recombinant
adenovirus vector
recombinant swine
nucleotide sequence
methods
Prior art date
Application number
DK98938527T
Other languages
Danish (da)
English (en)
Inventor
Michael Anthony Johnson
Jeffrey Michael Hammond
Original Assignee
Commw Scient Ind Res Org
Pig Res Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007088(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commw Scient Ind Res Org, Pig Res Dev Corp filed Critical Commw Scient Ind Res Org
Application granted granted Critical
Publication of DK1007088T3 publication Critical patent/DK1007088T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98938527T 1997-08-14 1998-08-14 Rekombinant svine-adenovirusvektor DK1007088T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8560A AUPO856097A0 (en) 1997-08-14 1997-08-14 Vector
PCT/AU1998/000648 WO1999008706A1 (en) 1997-08-14 1998-08-14 Recombinant porcine adenovirus vector

Publications (1)

Publication Number Publication Date
DK1007088T3 true DK1007088T3 (da) 2007-06-04

Family

ID=3802849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938527T DK1007088T3 (da) 1997-08-14 1998-08-14 Rekombinant svine-adenovirusvektor

Country Status (17)

Country Link
US (3) US7323177B1 (enExample)
EP (2) EP1825863A1 (enExample)
JP (2) JP4365023B2 (enExample)
KR (1) KR100746524B1 (enExample)
CN (1) CN100366292C (enExample)
AT (1) ATE357250T1 (enExample)
AU (2) AUPO856097A0 (enExample)
BR (1) BR9811184A (enExample)
CY (1) CY1106565T1 (enExample)
DE (1) DE69837390T2 (enExample)
DK (1) DK1007088T3 (enExample)
ES (1) ES2283068T3 (enExample)
ID (1) ID24174A (enExample)
MX (1) MXPA00001562A (enExample)
NZ (1) NZ503039A (enExample)
PT (1) PT1007088E (enExample)
WO (1) WO1999008706A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
WO2001083737A2 (en) * 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
WO2002031168A2 (en) * 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
SK287969B6 (sk) 2001-03-27 2012-08-06 University Of Saskatchewan Method to culture circovirus
WO2003013598A2 (en) * 2001-08-09 2003-02-20 Lam Dominic M K Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
EP1432791B2 (en) 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
JP3949520B2 (ja) * 2001-09-20 2007-07-25 独立行政法人科学技術振興機構 レギュカルチン過剰発現モデル動物
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
KR20030054139A (ko) * 2001-12-24 2003-07-02 학교법인 건국대학교 돼지 오제스키병 바이러스의 ｇＤ 유전자를 포함하는재조합 발현 벡터 및 이를 이용한 ＤＮＡ 백신
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
EP2290054B1 (en) 2002-12-13 2017-03-29 Alphavax, Inc. Alphavirus particles and methods for preparation
JP5016305B2 (ja) 2003-03-20 2012-09-05 アルファヴァックス，インコーポレイテッド 改良されたアルファウイルスレプリコンおよびヘルパー構築物
ATE432285T1 (de) 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
RU2389506C2 (ru) * 2005-09-09 2010-05-20 Интервет Интернэшнл Б.В. Вакцина против рсv-2
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
US20110135688A1 (en) * 2009-12-04 2011-06-09 Michael Sheppard Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors
CN105688201A (zh) * 2012-05-17 2016-06-22 佐蒂斯有限责任公司 在断奶之前对抗猪繁殖与呼吸综合征（prrs）病毒的有效疫苗接种
AU2015218769B2 (en) * 2014-02-20 2020-09-17 Vaxart, Inc. Formulations for small intestinal delivery
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
CA3047294A1 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
CN110904127B (zh) * 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
CN116981697A (zh) 2021-01-14 2023-10-31 森迪生物科学公司 可分泌有效载荷调节

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320068C1 (de) 1993-06-17 1994-12-15 Audi Ag Verfahren und Vorrichtung zur Reparatur von Fahrzeugkarosserien aus Leichtmetallteilen
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
EP0770157A4 (en) 1994-07-14 1998-01-07 Union Camp Patent Holding IMPROVED BLEACHING OF A VERY CONCENTRATED LIGNOCELLULOSIC PASTE
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
ES2105984B1 (es) * 1995-11-30 1998-04-16 Iberica Cyanamid Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome

Also Published As

Publication number Publication date
JP4365023B2 (ja) 2009-11-18
AU2011224111A1 (en) 2011-10-13
JP2009213495A (ja) 2009-09-24
CN1275084A (zh) 2000-11-29
HK1032755A1 (zh) 2001-08-03
EP1007088A4 (en) 2003-01-08
ATE357250T1 (de) 2007-04-15
US7323177B1 (en) 2008-01-29
US20090226485A1 (en) 2009-09-10
WO1999008706A8 (en) 2000-08-10
AUPO856097A0 (en) 1997-09-04
EP1007088A1 (en) 2000-06-14
ID24174A (id) 2000-07-13
DE69837390T2 (de) 2007-08-23
US7785602B2 (en) 2010-08-31
PT1007088E (pt) 2007-05-31
EP1007088B1 (en) 2007-03-21
US20060263387A1 (en) 2006-11-23
NZ503039A (en) 2002-09-27
MXPA00001562A (es) 2004-10-14
BR9811184A (pt) 2001-12-26
WO1999008706A1 (en) 1999-02-25
KR100746524B1 (ko) 2007-08-07
CN100366292C (zh) 2008-02-06
US7473428B2 (en) 2009-01-06
DE69837390D1 (de) 2007-05-03
EP1825863A1 (en) 2007-08-29
ES2283068T3 (es) 2007-10-16
KR20010022882A (ko) 2001-03-26
JP2001514871A (ja) 2001-09-18
CY1106565T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
DK1007088T3 (da) Rekombinant svine-adenovirusvektor
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
ES2130184T3 (es) Polipeptidos y vacunas recombinantes contra el herpesvirus bovino de tipo 1.
DK0439056T3 (da) Coccidiose-vacciner
DE69738641D1 (de) Lebend-impfstoff gegen heliobacter pylori
BR9508645B1 (pt) seqÜÊncia de nucleotÍdeos isolada compreendendo o gene s fipv tendo uma seqÜencia de nucleotÍdeos da cepa 79-1146 fipv, bem como polipeptÍdeo, vacina e composiÇço compreendendo a mesma.
BR0007855A (pt) Vacina de vìrus eliminado o gene bhv-1
GR3029665T3 (en) 16 kDa SURFACE PROTEIN OF -i(P. FALCIPARUM).
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
NZ227943A (en) An antigen derived from the neck region of the rhoptries of merozoites and vaccine against plasmodium falciparum
ZA906667B (en) Antigens and polypeptides derived from babesia(12d3 antigen)